Revagenix
2 known investors
Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
Founders & leadership
RC
Ryan CirzCo-founder & CEO
AM
Andrew McCandlishCo-founder & COO
PS
Peter SmithChief Scientific Officer
DC
Daniel CloutierVP, Development
Investors · 2
Frequently asked questions
- What does Revagenix do?
- Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
- Who founded Revagenix?
- Revagenix was founded by Ryan Cirz, Andrew McCandlish.
- Who are Revagenix's investors?
- Revagenix's investors include Tenmile, Novo Holdings.